GSK plc (GSK) 10-Year Financial Performance & Capital Metrics

GSK •

HealthcareLarge PharmaVaccines and plasma-derived therapies

AboutGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.Show more

Revenue $31.95B +1.8%
EBITDA $10.71B +62.9%
Net Income $5.59B +117.1%
EPS (Diluted) 2.72 +119.4%
Gross Margin 72.54% +1.9%
EBITDA Margin 33.51% +60.0%
Operating Margin 21.95% +71.2%
Net Margin 17.5% +113.2%
ROE 38.54% +120.0%
ROIC 18.58% +90.7%
Debt/Equity 1.11 -14.4%
Interest Coverage 10.23 +67.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 31.1%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 18.2% free cash flow margin
✓Momentum leader: RS Rating 85 (top 15%)
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.8%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.94%

5Y5.58%

3Y2.9%

TTM1.83%

Profit (Net Income) CAGR

10Y-4.01%

5Y-0.56%

3Y-27.96%

TTM121.66%

EPS CAGR

10Y-4.48%

5Y-1%

3Y4.26%

TTM124.03%

ROCE

10Y Avg11.58%

5Y Avg12.05%

3Y Avg14.4%

Latest18.11%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	27.89B	30.19B	30.82B	33.75B	24.35B	24.7B	29.32B	30.33B	31.38B	31.95B
Revenue Growth %	16.58%	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	1.83%
Cost of Goods Sold+	9.29B	10.34B	10.24B	11.86B	7.93B	8.16B	9.55B	8.56B	9.05B	8.77B
COGS % of Revenue	33.31%	34.26%	33.23%	35.15%	32.56%	33.05%	32.58%	28.24%	28.84%	27.46%
Gross Profit+	18.6B	19.84B	20.58B	21.89B	16.43B	16.53B	19.77B	21.76B	22.33B	23.18B
Gross Margin %	66.69%	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.54%
Gross Profit Growth %	23.42%	6.69%	3.71%	6.37%	-24.97%	0.66%	19.58%	10.08%	2.6%	3.81%
Operating Expenses+	16B	15.76B	15.1B	14.93B	10.45B	12.18B	13.34B	15.02B	18.31B	16.17B
OpEx % of Revenue	57.37%	52.2%	48.98%	44.23%	42.89%	49.3%	45.48%	49.52%	58.35%	50.6%
Selling, General & Admin	9.37B	9.67B	9.91B	11.4B	7.44B	7.07B	8.37B	9.38B	11.02B	8.82B
SG&A % of Revenue	33.58%	32.04%	32.17%	33.78%	30.54%	28.63%	28.55%	30.95%	35.11%	27.62%
Research & Development	3.63B	4.48B	3.89B	4.57B	4.79B	5.02B	5.49B	6.22B	6.4B	7.34B
R&D % of Revenue	13.01%	14.83%	12.63%	13.53%	19.68%	20.32%	18.71%	20.52%	20.4%	22.98%
Other Operating Expenses	3.01B	1.61B	1.29B	-1.04B	-1.78B	87M	-523M	-590M	891M	0
Operating Income+	2.6B	4.09B	5.48B	6.96B	5.98B	4.36B	6.43B	6.75B	4.02B	7.01B
Operating Margin %	9.32%	13.54%	17.79%	20.62%	24.55%	17.64%	21.94%	22.24%	12.82%	21.95%
Operating Income Growth %	-74.83%	57.31%	34.16%	26.96%	-14.11%	-27.13%	47.65%	4.85%	-40.39%	74.38%
EBITDA+	4.37B	6.01B	7.34B	9.08B	8.03B	6.48B	8.58B	9.04B	6.57B	10.71B
EBITDA Margin %	15.68%	19.91%	23.81%	26.9%	32.97%	26.24%	29.26%	29.8%	20.95%	33.51%
EBITDA Growth %	-63.42%	37.44%	22.13%	23.74%	-11.58%	-19.3%	32.43%	5.35%	-27.29%	62.92%
D&A (Non-Cash Add-back)	1.77B	1.92B	1.86B	2.12B	2.05B	2.12B	2.15B	2.29B	2.55B	3.7B
EBIT	2.66B	4.26B	5.49B	7.1B	6.02B	4.36B	6.45B	6.79B	4.12B	7.93B
Net Interest Income+	-662M	-667M	-665.8M	-810.89M	-852M	-755M	-791.26M	-735M	-590.19M	-520.34M
Interest Income	72M	65M	77.83M	98M	44M	28M	64.27M	40M	67.39M	165.3M
Interest Expense	736M	734M	743.64M	912M	892M	784M	855.53M	775M	657.58M	685.64M
Other Income/Expense	-659M	-562M	-683M	-740M	-809M	-758M	-805M	-681M	-544M	226.92M
Pretax Income+	1.94B	3.52B	4.8B	6.22B	5.17B	3.6B	5.63B	6.06B	3.48B	7.24B
Pretax Margin %	6.95%	11.68%	15.57%	18.43%	21.23%	14.57%	19.19%	19.99%	11.08%	22.66%
Income Tax+	877M	1.36B	754M	953M	67M	83M	707M	756M	526M	1.09B
Effective Tax Rate %	47.03%	43.46%	75.48%	74.67%	111.2%	121.84%	265.74%	81.27%	74.06%	77.23%
Net Income+	912M	1.53B	3.62B	4.64B	5.75B	4.38B	14.96B	4.93B	2.58B	5.59B
Net Margin %	3.27%	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%
Net Income Growth %	-89.17%	67.98%	136.49%	28.21%	23.77%	-23.73%	241.07%	-67.05%	-47.75%	117.12%
Net Income (Continuing)	1.06B	2.17B	4.05B	5.27B	5.1B	3.52B	4.92B	5.31B	2.95B	6.15B
Discontinued Operations	0	0	0	0	1.28B	1.58B	10.7B	0	0	0
Minority Interest	3.84B	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M
EPS (Diluted)+	0.46	0.78	1.82	2.32	2.86	2.70	2.40	2.40	1.24	2.72
EPS Growth %	-89.3%	69.57%	133.33%	27.47%	23.28%	-5.59%	-11.11%	0%	-48.33%	119.35%
EPS (Basic)	0.48	0.78	1.84	2.34	2.88	2.74	2.44	2.44	1.26	2.76
Diluted Shares Outstanding	1.96B	1.98B	1.99B	2.01B	2.02B	1.62B	2.04B	2.06B	2.07B	2.06B
Basic Shares Outstanding	1.94B	1.95B	1.97B	1.98B	1.99B	1.6B	2.01B	2.03B	2.04B	2.03B
Dividend Payout Ratio	531.8%	254.96%	108.39%	85.1%	69.18%	91.2%	28.55%	56.68%	94.91%	44.86%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	16.71B	15.91B	16.93B	25.82B	27.68B	25.29B	20.77B	23.77B	17B	17.48B
Cash & Short-Term Investments	4.99B	3.91B	3.96B	6.34B	8.71B	5.87B	7.88B	6.61B	3.71B	3.4B
Cash Only	4.9B	3.83B	3.87B	6.24B	8.6B	5.79B	3.72B	3.74B	3.69B	3.39B
Short-Term Investments	89M	78M	84M	104.66M	106.62M	82.62M	4.15B	2.86B	21M	8.98M
Accounts Receivable	5.69B	5.69B	6.32B	9.47B	9.93B	10.88B	6.22B	9.44B	6B	7.75B
Days Sales Outstanding	74.48	68.83	74.87	102.4	148.82	160.77	77.4	113.58	69.79	88.48
Inventory	5.1B	5.56B	5.48B	7.88B	8.2B	7.83B	5.15B	7.01B	5.67B	5.91B
Days Inventory Outstanding	200.46	196.12	195.17	242.4	377.3	350.23	196.6	298.68	228.69	246.05
Other Current Assets	1.54B	1.4B	841M	1.71B	352.67M	284.43M	1.1B	262.61M	1.23B	420.26M
Total Non-Current Assets+	42.37B	40.47B	41.14B	79.75B	82.27B	81.85B	39.38B	51.45B	42.47B	43.53B
Property, Plant & Equipment	10.81B	10.86B	11.06B	14.99B	15.04B	14.45B	9.62B	12.69B	10.07B	10.03B
Fixed Asset Turnover	2.58x	2.78x	2.79x	2.25x	1.62x	1.71x	3.05x	2.39x	3.11x	3.19x
Goodwill	5.96B	5.73B	5.79B	13.99B	14.49B	14.29B	7.05B	8.68B	6.98B	7.01B
Intangible Assets	18.78B	17.56B	17.2B	41.01B	40.77B	40.74B	14.32B	18.83B	15.52B	16.72B
Long-Term Investments	1.16B	1.02B	1.47B	3.18B	4.83B	4.29B	-2.61B	2.73B	1.21B	1.12B
Other Non-Current Assets	1.29B	1.5B	1.73B	1.15B	1.28B	1B	5.35B	808.22M	1.93B	2.14B
Total Assets+	59.08B	56.38B	58.07B	105.57B	109.95B	107.14B	60.15B	75.22B	59.46B	61.01B
Asset Turnover	0.47x	0.54x	0.53x	0.32x	0.22x	0.23x	0.49x	0.40x	0.53x	0.52x
Asset Growth %	10.54%	-4.57%	2.99%	81.81%	4.14%	-2.55%	-43.86%	25.06%	-20.95%	2.6%
Total Current Liabilities+	19B	26.57B	22.49B	31.86B	30.28B	32.06B	22.81B	26.86B	21.7B	21.35B
Accounts Payable	3.6B	3.53B	3.65B	5.49B	5.96B	6.14B	3.87B	4.74B	3.46B	15.35B
Days Payables Outstanding	141.29	124.51	129.91	168.91	274.17	274.65	147.7	201.93	139.66	638.84
Short-Term Debt	4.11B	2.8B	5.77B	9.16B	5.09B	4.88B	3.79B	3.59B	2.18B	3.01B
Deferred Revenue (Current)	2.35B	1.7B	1.82B	209.31M	493.47M	415.82M	0	283.01M	0	0
Other Current Liabilities	8.58B	12.68B	10.52B	14.22B	16.03B	17.97B	14.1B	15.25B	14.76B	2.5B
Current Ratio	0.88x	0.60x	0.75x	0.81x	0.91x	0.79x	0.91x	0.88x	0.78x	0.82x
Quick Ratio	0.61x	0.39x	0.51x	0.56x	0.64x	0.54x	0.68x	0.62x	0.52x	0.54x
Cash Conversion Cycle	133.65	140.44	140.13	175.89	251.95	236.35	126.3	210.33	158.82	-304.31
Total Non-Current Liabilities+	35.12B	26.32B	31.9B	49.39B	51.23B	46.17B	27.24B	32.05B	24.68B	23.66B
Long-Term Debt	14.62B	14.22B	20.23B	29.91B	30.81B	26.76B	16.19B	18.04B	13.7B	14.68B
Capital Lease Obligations	41M	43M	44M	1.34B	1.21B	1.1B	841M	1.34B	934M	0
Deferred Tax Liabilities	1.93B	1.4B	1.16B	5.05B	4.92B	4.82B	289M	396.46M	382M	290.49M
Other Non-Current Liabilities	18.46B	10.56B	10.46B	13.06B	14.26B	13.38B	9.83B	11.95B	9.5B	8.69B
Total Liabilities	54.12B	52.89B	54.39B	81.25B	81.5B	78.23B	50.05B	58.91B	46.38B	45.02B
Total Debt+	18.79B	17.09B	26.06B	40.42B	37.11B	32.74B	20.99B	22.97B	16.99B	17.69B
Net Debt	13.89B	13.26B	22.19B	34.18B	28.51B	26.95B	17.26B	19.23B	13.29B	14.3B
Debt / Equity	3.79x	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x
Debt / EBITDA	4.30x	2.84x	3.55x	4.45x	4.62x	5.05x	2.45x	2.54x	2.58x	1.65x
Net Debt / EBITDA	3.18x	2.21x	3.02x	3.76x	3.55x	4.16x	2.01x	2.13x	2.02x	1.34x
Interest Coverage	3.53x	5.57x	7.37x	7.63x	6.70x	5.56x	7.52x	8.70x	6.11x	10.23x
Total Equity+	4.96B	3.49B	3.67B	24.32B	28.44B	28.91B	10.1B	16.31B	13.09B	15.93B
Equity Growth %	-44.1%	-29.7%	5.25%	562.27%	16.96%	1.63%	-65.07%	61.56%	-19.77%	21.72%
Book Value per Share	2.53	1.77	1.85	12.12	14.11	17.83	4.94	7.94	6.32	7.74
Total Shareholders' Equity	1.12B	-68M	4.36B	15.11B	19.94B	20.39B	10.6B	17.01B	13.67B	16.35B
Common Stock	1.34B	1.34B	1.34B	1.78B	1.84B	1.82B	1.35B	1.72B	1.35B	1.35B
Retained Earnings	-5.39B	-6.48B	-2.14B	8.45B	11.76B	13.26B	4.36B	9.23B	7.8B	10.19B
Treasury Stock	-286M	-400M	-161M	-178.84M	-266.56M	-37.92M	0	-367.14M	0	0
Accumulated OCI	657M	598M	373M	849.16M	2.12B	869.56M	0	2.04B	0	0
Minority Interest	3.84B	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	6.5B	6.92B	8.42B	8.02B	8.44B	7.95B	8.16B	7.89B	6.55B	7.14B
Operating CF Margin %	23.3%	22.92%	27.32%	23.76%	34.66%	32.2%	27.83%	26.02%	20.89%	22.36%
Operating CF Growth %	152.9%	6.48%	21.73%	-4.76%	5.25%	-5.79%	2.62%	-3.3%	-16.94%	8.99%
Net Income	1.06B	2.17B	4.05B	5.27B	5.1B	3.52B	5.49B	6.13B	2.95B	5.59B
Depreciation & Amortization	1.86B	2.98B	1.76B	3B	2.05B	2.12B	2.64B	2.85B	2.55B	3.7B
Stock-Based Compensation	319M	333M	360M	365M	337M	343M	0	0	344M	0
Deferred Taxes	2.61B	1.5B	1.78B	-1.95B	0	0	-965.72M	-1.08B	0	0
Other Non-Cash Items	664M	669M	717M	814M	-1.24B	584M	2.66B	1.05B	-1.38B	-1.53B
Working Capital Changes	-22M	-737M	-247M	531M	2.19B	1.39B	-1.67B	-1.06B	2.09B	-608.37M
Change in Receivables	193M	-213M	-411M	-192M	-628M	-1.16B	-758.78M	-806.74M	340M	0
Change in Inventory	70M	-461M	51M	300M	100M	51M	-331.35M	-527.05M	-294M	0
Change in Payables	96M	11M	131M	263M	0	0	608.5M	-18.65M	0	0
Cash from Investing+	-1.27B	-1.44B	-1.55B	-5.35B	2.16B	-1.78B	-10.88B	-2.4B	-1.23B	-5.72B
Capital Expenditures	-2.35B	-2.2B	-1.8B	-2.16B	-989M	-950M	-2.78B	-2.91B	-1.4B	-2.92B
CapEx % of Revenue	8.43%	7.29%	5.83%	6.41%	4.06%	3.85%	9.48%	9.61%	4.46%	9.14%
Acquisitions	592M	356M	-292M	-3.78B	2.85B	185M	-3.79B	-1.72B	1.37B	-4.37B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	736M	395M	1.3B	846M	-2.97B	-1.03B	-4.43B	14.92M	-1.22B	1.46B
Cash from Financing+	-6.39B	-6.38B	-6.39B	-1.84B	-10.13B	-7.59B	2.05B	-6.07B	-4.73B	-1.59B
Debt Issued (Net)	-18M	-990M	8.15B	3.73B	-4.03B	-2B	-5.69B	-2.95B	-1.17B	1.47B
Equity Issued (Net)	-1000K	-1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	-4.85B	-3.91B	-3.93B	-3.95B	-3.98B	-4B	-4.27B	-2.79B	-2.44B	-2.51B
Share Repurchases	-74M	-65M	0	0	0	0	0	0	0	0
Other Financing	-1.45B	-1.48B	-10.69B	-1.67B	-2.15B	-1.61B	11.98B	-341.84M	-1.14B	-573.16M
Net Change in Cash	-881M	-1B	487M	744M	431M	-1.44B	-1.31B	-735.58M	545M	-206.06M
Free Cash Flow+	4.14B	4.72B	6.63B	5.86B	6.5B	5.3B	6.75B	6.26B	3.57B	5.82B
FCF Margin %	14.86%	15.62%	21.5%	17.35%	26.67%	21.45%	23.03%	20.63%	11.38%	18.23%
FCF Growth %	520.51%	13.78%	40.48%	-11.59%	10.91%	-18.44%	27.46%	-7.33%	-42.92%	63.06%
FCF per Share	2.11	2.39	3.33	2.92	3.22	3.27	3.31	3.04	1.72	2.83
FCF Conversion (FCF/Net Income)	7.12x	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.28x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	13.18%	36.25%	101.19%	33.19%	21.79%	15.29%	76.69%	37.32%	17.52%	38.54%
Return on Invested Capital (ROIC)	10.11%	17.22%	19.3%	12.38%	7.77%	5.79%	11.6%	16.09%	9.74%	18.58%
Gross Margin	66.69%	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.54%
Net Margin	3.27%	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%
Debt / Equity	3.79x	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x
Interest Coverage	3.53x	5.57x	7.37x	7.63x	6.70x	5.56x	7.52x	8.70x	6.11x	10.23x
FCF Conversion	7.12x	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.28x
Revenue Growth	16.58%	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	1.83%

US Stock Screener

...

GSK plc (GSK) 10-Year Financial Performance & Capital Metrics

GSK •

HealthcareLarge PharmaVaccines and plasma-derived therapies

Revenue $31.95B +1.8%
EBITDA $10.71B +62.9%
Net Income $5.59B +117.1%
EPS (Diluted) 2.72 +119.4%
Gross Margin 72.54% +1.9%
EBITDA Margin 33.51% +60.0%
Operating Margin 21.95% +71.2%
Net Margin 17.5% +113.2%
ROE 38.54% +120.0%
ROIC 18.58% +90.7%
Debt/Equity 1.11 -14.4%
Interest Coverage 10.23 +67.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 31.1%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 18.2% free cash flow margin
✓Momentum leader: RS Rating 85 (top 15%)
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.8%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.94%

5Y5.58%

3Y2.9%

TTM1.83%

Profit (Net Income) CAGR

10Y-4.01%

5Y-0.56%

3Y-27.96%

TTM121.66%

EPS CAGR

10Y-4.48%

5Y-1%

3Y4.26%

TTM124.03%

ROCE

10Y Avg11.58%

5Y Avg12.05%

3Y Avg14.4%

Latest18.11%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	27.89B	30.19B	30.82B	33.75B	24.35B	24.7B	29.32B	30.33B	31.38B	31.95B
Revenue Growth %	16.58%	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	1.83%
Cost of Goods Sold+	9.29B	10.34B	10.24B	11.86B	7.93B	8.16B	9.55B	8.56B	9.05B	8.77B
COGS % of Revenue	33.31%	34.26%	33.23%	35.15%	32.56%	33.05%	32.58%	28.24%	28.84%	27.46%
Gross Profit+	18.6B	19.84B	20.58B	21.89B	16.43B	16.53B	19.77B	21.76B	22.33B	23.18B
Gross Margin %	66.69%	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.54%
Gross Profit Growth %	23.42%	6.69%	3.71%	6.37%	-24.97%	0.66%	19.58%	10.08%	2.6%	3.81%
Operating Expenses+	16B	15.76B	15.1B	14.93B	10.45B	12.18B	13.34B	15.02B	18.31B	16.17B
OpEx % of Revenue	57.37%	52.2%	48.98%	44.23%	42.89%	49.3%	45.48%	49.52%	58.35%	50.6%
Selling, General & Admin	9.37B	9.67B	9.91B	11.4B	7.44B	7.07B	8.37B	9.38B	11.02B	8.82B
SG&A % of Revenue	33.58%	32.04%	32.17%	33.78%	30.54%	28.63%	28.55%	30.95%	35.11%	27.62%
Research & Development	3.63B	4.48B	3.89B	4.57B	4.79B	5.02B	5.49B	6.22B	6.4B	7.34B
R&D % of Revenue	13.01%	14.83%	12.63%	13.53%	19.68%	20.32%	18.71%	20.52%	20.4%	22.98%
Other Operating Expenses	3.01B	1.61B	1.29B	-1.04B	-1.78B	87M	-523M	-590M	891M	0
Operating Income+	2.6B	4.09B	5.48B	6.96B	5.98B	4.36B	6.43B	6.75B	4.02B	7.01B
Operating Margin %	9.32%	13.54%	17.79%	20.62%	24.55%	17.64%	21.94%	22.24%	12.82%	21.95%
Operating Income Growth %	-74.83%	57.31%	34.16%	26.96%	-14.11%	-27.13%	47.65%	4.85%	-40.39%	74.38%
EBITDA+	4.37B	6.01B	7.34B	9.08B	8.03B	6.48B	8.58B	9.04B	6.57B	10.71B
EBITDA Margin %	15.68%	19.91%	23.81%	26.9%	32.97%	26.24%	29.26%	29.8%	20.95%	33.51%
EBITDA Growth %	-63.42%	37.44%	22.13%	23.74%	-11.58%	-19.3%	32.43%	5.35%	-27.29%	62.92%
D&A (Non-Cash Add-back)	1.77B	1.92B	1.86B	2.12B	2.05B	2.12B	2.15B	2.29B	2.55B	3.7B
EBIT	2.66B	4.26B	5.49B	7.1B	6.02B	4.36B	6.45B	6.79B	4.12B	7.93B
Net Interest Income+	-662M	-667M	-665.8M	-810.89M	-852M	-755M	-791.26M	-735M	-590.19M	-520.34M
Interest Income	72M	65M	77.83M	98M	44M	28M	64.27M	40M	67.39M	165.3M
Interest Expense	736M	734M	743.64M	912M	892M	784M	855.53M	775M	657.58M	685.64M
Other Income/Expense	-659M	-562M	-683M	-740M	-809M	-758M	-805M	-681M	-544M	226.92M
Pretax Income+	1.94B	3.52B	4.8B	6.22B	5.17B	3.6B	5.63B	6.06B	3.48B	7.24B
Pretax Margin %	6.95%	11.68%	15.57%	18.43%	21.23%	14.57%	19.19%	19.99%	11.08%	22.66%
Income Tax+	877M	1.36B	754M	953M	67M	83M	707M	756M	526M	1.09B
Effective Tax Rate %	47.03%	43.46%	75.48%	74.67%	111.2%	121.84%	265.74%	81.27%	74.06%	77.23%
Net Income+	912M	1.53B	3.62B	4.64B	5.75B	4.38B	14.96B	4.93B	2.58B	5.59B
Net Margin %	3.27%	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%
Net Income Growth %	-89.17%	67.98%	136.49%	28.21%	23.77%	-23.73%	241.07%	-67.05%	-47.75%	117.12%
Net Income (Continuing)	1.06B	2.17B	4.05B	5.27B	5.1B	3.52B	4.92B	5.31B	2.95B	6.15B
Discontinued Operations	0	0	0	0	1.28B	1.58B	10.7B	0	0	0
Minority Interest	3.84B	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M
EPS (Diluted)+	0.46	0.78	1.82	2.32	2.86	2.70	2.40	2.40	1.24	2.72
EPS Growth %	-89.3%	69.57%	133.33%	27.47%	23.28%	-5.59%	-11.11%	0%	-48.33%	119.35%
EPS (Basic)	0.48	0.78	1.84	2.34	2.88	2.74	2.44	2.44	1.26	2.76
Diluted Shares Outstanding	1.96B	1.98B	1.99B	2.01B	2.02B	1.62B	2.04B	2.06B	2.07B	2.06B
Basic Shares Outstanding	1.94B	1.95B	1.97B	1.98B	1.99B	1.6B	2.01B	2.03B	2.04B	2.03B
Dividend Payout Ratio	531.8%	254.96%	108.39%	85.1%	69.18%	91.2%	28.55%	56.68%	94.91%	44.86%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	16.71B	15.91B	16.93B	25.82B	27.68B	25.29B	20.77B	23.77B	17B	17.48B
Cash & Short-Term Investments	4.99B	3.91B	3.96B	6.34B	8.71B	5.87B	7.88B	6.61B	3.71B	3.4B
Cash Only	4.9B	3.83B	3.87B	6.24B	8.6B	5.79B	3.72B	3.74B	3.69B	3.39B
Short-Term Investments	89M	78M	84M	104.66M	106.62M	82.62M	4.15B	2.86B	21M	8.98M
Accounts Receivable	5.69B	5.69B	6.32B	9.47B	9.93B	10.88B	6.22B	9.44B	6B	7.75B
Days Sales Outstanding	74.48	68.83	74.87	102.4	148.82	160.77	77.4	113.58	69.79	88.48
Inventory	5.1B	5.56B	5.48B	7.88B	8.2B	7.83B	5.15B	7.01B	5.67B	5.91B
Days Inventory Outstanding	200.46	196.12	195.17	242.4	377.3	350.23	196.6	298.68	228.69	246.05
Other Current Assets	1.54B	1.4B	841M	1.71B	352.67M	284.43M	1.1B	262.61M	1.23B	420.26M
Total Non-Current Assets+	42.37B	40.47B	41.14B	79.75B	82.27B	81.85B	39.38B	51.45B	42.47B	43.53B
Property, Plant & Equipment	10.81B	10.86B	11.06B	14.99B	15.04B	14.45B	9.62B	12.69B	10.07B	10.03B
Fixed Asset Turnover	2.58x	2.78x	2.79x	2.25x	1.62x	1.71x	3.05x	2.39x	3.11x	3.19x
Goodwill	5.96B	5.73B	5.79B	13.99B	14.49B	14.29B	7.05B	8.68B	6.98B	7.01B
Intangible Assets	18.78B	17.56B	17.2B	41.01B	40.77B	40.74B	14.32B	18.83B	15.52B	16.72B
Long-Term Investments	1.16B	1.02B	1.47B	3.18B	4.83B	4.29B	-2.61B	2.73B	1.21B	1.12B
Other Non-Current Assets	1.29B	1.5B	1.73B	1.15B	1.28B	1B	5.35B	808.22M	1.93B	2.14B
Total Assets+	59.08B	56.38B	58.07B	105.57B	109.95B	107.14B	60.15B	75.22B	59.46B	61.01B
Asset Turnover	0.47x	0.54x	0.53x	0.32x	0.22x	0.23x	0.49x	0.40x	0.53x	0.52x
Asset Growth %	10.54%	-4.57%	2.99%	81.81%	4.14%	-2.55%	-43.86%	25.06%	-20.95%	2.6%
Total Current Liabilities+	19B	26.57B	22.49B	31.86B	30.28B	32.06B	22.81B	26.86B	21.7B	21.35B
Accounts Payable	3.6B	3.53B	3.65B	5.49B	5.96B	6.14B	3.87B	4.74B	3.46B	15.35B
Days Payables Outstanding	141.29	124.51	129.91	168.91	274.17	274.65	147.7	201.93	139.66	638.84
Short-Term Debt	4.11B	2.8B	5.77B	9.16B	5.09B	4.88B	3.79B	3.59B	2.18B	3.01B
Deferred Revenue (Current)	2.35B	1.7B	1.82B	209.31M	493.47M	415.82M	0	283.01M	0	0
Other Current Liabilities	8.58B	12.68B	10.52B	14.22B	16.03B	17.97B	14.1B	15.25B	14.76B	2.5B
Current Ratio	0.88x	0.60x	0.75x	0.81x	0.91x	0.79x	0.91x	0.88x	0.78x	0.82x
Quick Ratio	0.61x	0.39x	0.51x	0.56x	0.64x	0.54x	0.68x	0.62x	0.52x	0.54x
Cash Conversion Cycle	133.65	140.44	140.13	175.89	251.95	236.35	126.3	210.33	158.82	-304.31
Total Non-Current Liabilities+	35.12B	26.32B	31.9B	49.39B	51.23B	46.17B	27.24B	32.05B	24.68B	23.66B
Long-Term Debt	14.62B	14.22B	20.23B	29.91B	30.81B	26.76B	16.19B	18.04B	13.7B	14.68B
Capital Lease Obligations	41M	43M	44M	1.34B	1.21B	1.1B	841M	1.34B	934M	0
Deferred Tax Liabilities	1.93B	1.4B	1.16B	5.05B	4.92B	4.82B	289M	396.46M	382M	290.49M
Other Non-Current Liabilities	18.46B	10.56B	10.46B	13.06B	14.26B	13.38B	9.83B	11.95B	9.5B	8.69B
Total Liabilities	54.12B	52.89B	54.39B	81.25B	81.5B	78.23B	50.05B	58.91B	46.38B	45.02B
Total Debt+	18.79B	17.09B	26.06B	40.42B	37.11B	32.74B	20.99B	22.97B	16.99B	17.69B
Net Debt	13.89B	13.26B	22.19B	34.18B	28.51B	26.95B	17.26B	19.23B	13.29B	14.3B
Debt / Equity	3.79x	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x
Debt / EBITDA	4.30x	2.84x	3.55x	4.45x	4.62x	5.05x	2.45x	2.54x	2.58x	1.65x
Net Debt / EBITDA	3.18x	2.21x	3.02x	3.76x	3.55x	4.16x	2.01x	2.13x	2.02x	1.34x
Interest Coverage	3.53x	5.57x	7.37x	7.63x	6.70x	5.56x	7.52x	8.70x	6.11x	10.23x
Total Equity+	4.96B	3.49B	3.67B	24.32B	28.44B	28.91B	10.1B	16.31B	13.09B	15.93B
Equity Growth %	-44.1%	-29.7%	5.25%	562.27%	16.96%	1.63%	-65.07%	61.56%	-19.77%	21.72%
Book Value per Share	2.53	1.77	1.85	12.12	14.11	17.83	4.94	7.94	6.32	7.74
Total Shareholders' Equity	1.12B	-68M	4.36B	15.11B	19.94B	20.39B	10.6B	17.01B	13.67B	16.35B
Common Stock	1.34B	1.34B	1.34B	1.78B	1.84B	1.82B	1.35B	1.72B	1.35B	1.35B
Retained Earnings	-5.39B	-6.48B	-2.14B	8.45B	11.76B	13.26B	4.36B	9.23B	7.8B	10.19B
Treasury Stock	-286M	-400M	-161M	-178.84M	-266.56M	-37.92M	0	-367.14M	0	0
Accumulated OCI	657M	598M	373M	849.16M	2.12B	869.56M	0	2.04B	0	0
Minority Interest	3.84B	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	6.5B	6.92B	8.42B	8.02B	8.44B	7.95B	8.16B	7.89B	6.55B	7.14B
Operating CF Margin %	23.3%	22.92%	27.32%	23.76%	34.66%	32.2%	27.83%	26.02%	20.89%	22.36%
Operating CF Growth %	152.9%	6.48%	21.73%	-4.76%	5.25%	-5.79%	2.62%	-3.3%	-16.94%	8.99%
Net Income	1.06B	2.17B	4.05B	5.27B	5.1B	3.52B	5.49B	6.13B	2.95B	5.59B
Depreciation & Amortization	1.86B	2.98B	1.76B	3B	2.05B	2.12B	2.64B	2.85B	2.55B	3.7B
Stock-Based Compensation	319M	333M	360M	365M	337M	343M	0	0	344M	0
Deferred Taxes	2.61B	1.5B	1.78B	-1.95B	0	0	-965.72M	-1.08B	0	0
Other Non-Cash Items	664M	669M	717M	814M	-1.24B	584M	2.66B	1.05B	-1.38B	-1.53B
Working Capital Changes	-22M	-737M	-247M	531M	2.19B	1.39B	-1.67B	-1.06B	2.09B	-608.37M
Change in Receivables	193M	-213M	-411M	-192M	-628M	-1.16B	-758.78M	-806.74M	340M	0
Change in Inventory	70M	-461M	51M	300M	100M	51M	-331.35M	-527.05M	-294M	0
Change in Payables	96M	11M	131M	263M	0	0	608.5M	-18.65M	0	0
Cash from Investing+	-1.27B	-1.44B	-1.55B	-5.35B	2.16B	-1.78B	-10.88B	-2.4B	-1.23B	-5.72B
Capital Expenditures	-2.35B	-2.2B	-1.8B	-2.16B	-989M	-950M	-2.78B	-2.91B	-1.4B	-2.92B
CapEx % of Revenue	8.43%	7.29%	5.83%	6.41%	4.06%	3.85%	9.48%	9.61%	4.46%	9.14%
Acquisitions	592M	356M	-292M	-3.78B	2.85B	185M	-3.79B	-1.72B	1.37B	-4.37B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	736M	395M	1.3B	846M	-2.97B	-1.03B	-4.43B	14.92M	-1.22B	1.46B
Cash from Financing+	-6.39B	-6.38B	-6.39B	-1.84B	-10.13B	-7.59B	2.05B	-6.07B	-4.73B	-1.59B
Debt Issued (Net)	-18M	-990M	8.15B	3.73B	-4.03B	-2B	-5.69B	-2.95B	-1.17B	1.47B
Equity Issued (Net)	-1000K	-1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	-4.85B	-3.91B	-3.93B	-3.95B	-3.98B	-4B	-4.27B	-2.79B	-2.44B	-2.51B
Share Repurchases	-74M	-65M	0	0	0	0	0	0	0	0
Other Financing	-1.45B	-1.48B	-10.69B	-1.67B	-2.15B	-1.61B	11.98B	-341.84M	-1.14B	-573.16M
Net Change in Cash	-881M	-1B	487M	744M	431M	-1.44B	-1.31B	-735.58M	545M	-206.06M
Free Cash Flow+	4.14B	4.72B	6.63B	5.86B	6.5B	5.3B	6.75B	6.26B	3.57B	5.82B
FCF Margin %	14.86%	15.62%	21.5%	17.35%	26.67%	21.45%	23.03%	20.63%	11.38%	18.23%
FCF Growth %	520.51%	13.78%	40.48%	-11.59%	10.91%	-18.44%	27.46%	-7.33%	-42.92%	63.06%
FCF per Share	2.11	2.39	3.33	2.92	3.22	3.27	3.31	3.04	1.72	2.83
FCF Conversion (FCF/Net Income)	7.12x	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.28x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	13.18%	36.25%	101.19%	33.19%	21.79%	15.29%	76.69%	37.32%	17.52%	38.54%
Return on Invested Capital (ROIC)	10.11%	17.22%	19.3%	12.38%	7.77%	5.79%	11.6%	16.09%	9.74%	18.58%
Gross Margin	66.69%	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.54%
Net Margin	3.27%	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%
Debt / Equity	3.79x	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x
Interest Coverage	3.53x	5.57x	7.37x	7.63x	6.70x	5.56x	7.52x	8.70x	6.11x	10.23x
FCF Conversion	7.12x	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.28x
Revenue Growth	16.58%	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	1.83%

GSK plc (GSK) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare GSK vs Peers

vs MRK

vs PFE

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

GSK plc (GSK) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare GSK vs Peers

vs MRK

vs PFE

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios